Study points to new target for cancers resistant to Iressa and Herceptin

A more-sensitive method to analyze protein interactions has uncovered a new way that cancer cells may use the cell-surface molecule HER3 to drive tumor progression following treatment with HER1 and HER2 inhibitors. This study shows that HER3 could be up to 10 times more effective than HER2 in recruiting the proteins that drive the spread of cancer.

Read the whole article on Science Daily

More from Science Daily